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1.2 Abstract 
Introduction 
This secondary data analysis of a prospective cohort study set out to describe the 
association between the use of hormonal contraception and sexually transmitted 
infection (STI) acquisition in a cohort of 752 HIV negative women who were followed 
up for a year.  
Methods 
Outcome variables were measured by standard laboratory tests (PCR for Chlamydia 
trachomatis (CT) and Neiserria gonorrhoea (NG), culture for Trichomonas vaginalis 
(TV) and gram stain with Nugent score for Bacterial Vaginosis (BV). Exposure 
variable information was collected by structured interview.  Basic descriptive 
statistics were applied to describe the characteristics of the cohort, including a 
comparison of women who used contraception and those who did not. A time series 
analysis including incidence rates for the outcomes (CT, NG, TV and BV), Kaplan 
Meier curves for time to event measurement and Cox regression models (univariate 
and multivariate), for the estimation of risk were applied.  
Results 
The analysis found no significant difference between women who use hormonal 
contraception and those who did not with respect to baseline demographic 
characteristics. Incidence rates per 100 women years to follow up with 95% 
confidence intervals were: CT 13 (7 to 17), NG 2 (1 to 4), TV 6 (4 to10), BV 72 (63 to 
83). Kaplan Meier curves showed no significant difference in time to event between 
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women who used contraception and those who did not. Adjusted hazard ratios for 
women who used contraception was 1.12 (0.69 to1.82) for CT, 0.47 (0.17 to 1.30) 
for NG, 1.06 (0.48 to 2.34) for TV and 0.27 (0.05 to 1.52) for BV.  
Conclusion 
This analysis did not reveal any significant associations between the use of 
hormonal contraception and the acquisition of STIs, however the trends in risks 
follow those reported in the literature. 
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2.0   BACKGROUND AND LITERATURE REVIEW 
Sexually transmitted infections (STI) are still a major health concern in both the 
global and South African contexts. Factors contributing to this burden include 
individual physical factors, risk behavior factors, social and health care factors. Due 
to the high burden of disease and the associated morbidity, strategies to decrease 
the risk of acquiring STI are important. Hormonal contraception is widely used; if the 
use of hormonal contraception is an additional risk for acquiring sexually transmitted 
infection then strategies to address type of contraception use and dual use of barrier 
methods would be extremely important.  
 
2.1 Disease burden of sexually transmitted infection 
STIs are still a major public health concern despite effective antibiotic treatment for 
all the bacterial infections. Globally, on an annual basis, an estimated 150 million 
new cases of Chlamydia trachomatis (CT) and Neiserria gonorrhoea (NG) occur (1). 
The incidence of infections increases to 333 million cases when Treponema 
pallidum (Syphilis) and Trichomonas vaginalis (TV) are included (2). These treatable 
inflammatory bacterial infections are associated with severe complications including 
pelvis inflammatory disease, infertility and adverse pregnancy outcomes (3). An 
additional complication of STIs, particularly ulcerative infections, is HIV acquisition 
and transmission (4, 5). 
This large burden of disease is the second largest cause of the loss of healthy life 
years in women of reproductive ages in the developing world (6).  
2 
 
CT and NG infections are thought to lead to the loss of as many as 7 million 
disability adjusted life years (DALYs) (7). The burden of disease due to STIs in 
South Africa is estimated to be 49 000 DALY in 2000, with disease in women 
contributing to 31 000 of these DALYs (8). Factors contributing to this include 
migrant labour, poor access and quality of health care in disadvantaged 
communities, the socio-economic disadvantage of  women, low condom use, high 
level of urbanization (compared with other African countries) and a well developed 
transport system (8).  
In South Africa STIs are highly prevalent. In a survey of women attending rural 
family planning clinics the prevalence of NG was 3-4% and CT 8-12% (9, 10). South 
African young women, in a population based survey, were particularly affected with 
as many 5% of women aged 15 being infected with CT , increasing to 13% of 
women aged 24 (11).  Results from a study conducted in Kwa-Zulu Natal showed 
that 25% of women in the reproductive age group had at least one curable STI (CT, 
NG, TV or syphilis) on any given day (10). This alarming number is particularly 
concerning as half of these infections were asymptomatic (10).  
Only three studies have looked at trends over time and in these studies the 
prevalence of CT and syphilis in pregnant women in Hlabisa, Kwazulu Natal, 
declined significantly between 1995 and 2000 (3). However a series of surveys in 
Carltonville, North West Province, showed an increasing prevalence of syphilis, NG 
and CT (in men and women, in the general population and in high risk groups) 
between 1998 and 2000 (3).  In the same area, the detection of Herpes Simplex 
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Virus type 2 (HSV2) increased while the prevalence of syphilis remained unchanged 
in the period between 1993/4 and 1998 (12). 
The South African Department of Health conducts annual surveys of HIV and 
syphilis  prevalence in women attending antenatal clinics. These surveys report that 
the prevalence of syphilis has been declining since 1997 (3). The Department of 
Health also collects data on STI in public health clinics. These surveys have not 
described any significant trends in either direction (3). 
When compared with other African countries the burden of STIs in South Africa is 
high, with the prevalence of NG, CT and TV in South Africa higher than those 
reported in surveys conducted in several other African countries, including Tanzania, 
and Uganda (3).   
Although Bacterial Vaginosis (BV) has not been included in the classical definition of 
a STI it is the most common cause of symptomatic vaginal discharge in women of 
reproductive age (13). BV and the absence of lactobacilli are associated with sexual 
activity (14). The prevalence of BV ranges from 4% in college women in the USA,  to 
as much as 60% in some STI clinics (15). BV is associated with pelvic inflammatory 
disease, endometritis, infection after gynaecological procedures, increased risk of 
other sexually transmitted diseases, chorioamnionitis, premature labour and 
premature rupture of membranes (16). 
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2.2 Hormonal contraception use  
Hormonal contraception has provided many women with a family planning option 
that is safe, convenient and reliable. Global figures reflect that as many as 100 
million women worldwide use hormonal contraception, which includes the oral 
contraceptive pill and long acting progestin injectable: depot medroxyprogesterone 
acetate (DMPA) (17). It is estimated that 65 million women use the oral 
contraceptive world wide and 40 million of these are in the developing world (18). 
This is a 65% increase from 14 million women in 1977 (18).  In South Africa, 32% of 
currently sexually active women use injectable hormonal contraception and 56% of 
women aged 15 to 49 have used injectable hormonal contraception at some stage in 
their reproductive life time (19). There are two options for injectable contraception in 
South Africa, DMPA and Norethisterone Enanthate(NET-EN). There are very few 
countries that use NET-EN, and about 14% of injectable uses in South Africa use 
NET-EN (19).      
2.3 The link between the use of hormonal contraception and the acquisition 
of sexually transmitted infections 
The available published data includes cross sectional and prospective cohort 
studies. Most of the data concentrates on the association between the use of oral 
contraception and the acquisition of CT. Many of the studies are analyses of data 
collected for other purposes and so lacked the ability to adjust for confounders, the 
definition of exposure to hormone is not defined, or the use of barrier methods is not 
mentioned. Substantially more data is available describing the association between 
the use of hormonal contraception and the acquisition of HIV. The evidence to 
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support this is based in prospective cohort studies carried out in Kenya and 
Uganda(20, 21). In a population of commercial sex worker who used oral 
contraception the risk of acquiring HIV was 1.46 times that of women who did not 
use contraception (Hazard ratio(HR) 1.46 95% confidence interval (CI) 1.00 to 2.13).  
Women using DMPA were slightly more at risk of acquiring HIV than those women 
not using contraception (HR 1.76 95% CI 1.28 to 2.34).  A more general population 
cohort of women in Uganda did not have the same risk with incident rate ratios of 
1.12 (95%CI, 0.48 to 2.56 for oral contraception uses and 0.84 (95%CI, 0.41 to 
1.72). Many of the analyses conducted on the association between the use of 
contraception and the acquisition of bacterial STI are based on the same cohorts.     
2.3.1 C. trachomatis infections  
A quantitative review calculated a pooled odds ratio (OR) for 29 case-control studies 
for the association between the use of oral contraception and the acquisition of CT 
infections. A pooled summary crude OR of 1.93 (95% CI 1.7 to 2.1) was reported 
suggesting a significant increased risk of acquiring C. trachomatis  infection in 
women who used oral contraception (22). The authors also calculated odds ratios for 
those studies where confounding was not measured and this analysis did not alter 
the summary OR 1.92 (95% CI 1.73 to 2.12) significantly. There was little change to 
the odds ratio for studies that did adjust for confounders OR 1.98 (95% CI 1.67 to 
2.34). However, when comparing oral contraception users to users of barrier 
methods, women using barrier methods were 66% less likely to acquire CT 
infections. (OR 0.34 95% CI 0.22 to 0.54) (22).  
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Five prospective cohort studies, summarized in table 2.1, report associations 
between the use of hormonal contraception and the acquisition of CT. Three of 
these studies are in general population women: In Belgium the study reported a 
crude relative risk (RR) of 8.8 (95% CI 1.3 to 59) (22); In the United States of 
America (USA) the study reported an adjusted hazard ratio (AHR) of  4.3 (95% CI 
1.7 to 11.1) (24) and a single study, conducted in Sweden,  did not follow the trend 
and reported a crude OR of 0.67 (95% CI 0.27 to 1.68) (34).   In addition two studies 
drew cohorts from commercial sex workers (CSW) in Kenya and reported an AHR of 
1.5 (95% CI 1.1 to 2.9) for the association between the use of oral contraception and 
acquisition of CT infections in HIV negative women and an AHR of 2.2 (95% CI 0.7 
to 7.3) in HIV positive women (25, 45).  
Similar increased risks are reported for the association between the use of DMPA 
and the acquisition of CT infections. Adjusted hazard ratios of 1.6 (95% CI 1.1 to 
2.4), 3.1 (95% CI 1.0 to 9.4) and 4.3 (95% CI 1.7 to 11.1) are reported (24, 25).  In 
two studies presented at an international conference in 2007, but not yet published, 
very similar results are reported. Morrison et al in a study conducted in three 
countries reports AHR for OC uses of 1.39 95% CI 1.09 to 1.77) and AHR for DMPA 
uses of 1.09 (95% CI 0.84-1.41(47). Pettifor et al in a smaller study reports an 
adjusted rate ratio of 1. 04(95% CI 0.62-1.76) (48).  
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2.3.2 N. gonorrhoea infections 
There is much less published literature on the association between the use of oral 
contraception and the acquisition of NG infections. A review of 21 cross sectional 
studies reported associations in only four studies. In these studies the risk of NG 
infection among oral contraception users varied with adjusted odds ratios (AOR) 
ranging from 1.53-5.25 (95% CI 1.09 to 26.25) being reported (26). Similar finding 
were presented at an international conference AHR 1.39 (95% CI 1.09-1.77) (47). 
Interestingly in the presence of DMPA use, cross sectional studies reported a 
decreased (but not significant) odds of acquiring NG infection OR 0.23 (95% CI 0.01 
to 2.37) when compared to IUD users, and an OR 0.23 (95% CI 0.01 to 3.65) when 
compared to women using not using contraception (24). Prospective studies report 
no difference in risk with adjusted HR 1.1 (95% CI 0.8 to 1.6) and 1.0 (95% CI 0.6 to 
1.7) reported (25, 45). Similar results were presented at an international conference 
from two studies of women using DMPA with AHR 1.50 (95% CI 1.10-2.05) and ARR 
of 1.02(95% CI 0.5-2.11) (47, 48).  
2.3.3 T. vaginalis infections 
Data describing the association between the use of oral contraception and the 
acquisition of TV are divided on whether there is any risk association. Cross 
sectional data reports non significant associations including decreased and 
increased odds of infection (odd ratios ranging from 0.4 to 3.96 (95% CI 0.14 to 
88.65). Significant results, all with a protective association, range from OR of 0.38 to 
0.71 (95% CIs 0.15-0.98) (26).  Prospective cohort study data follows the decreased 
risk trend with an AHR of 0.9 (95% CI 0.7-1.3) reported (26). Evidence linking the 
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use of DMPA with TV infection is based on a single cross sectional study reporting 
OR 1.0 (95% CI 0.19-1.3) (26) and a single prospective study reporting an AHR of 
0.6 (95% CI 0.4-1.0) (25). A study presented at an international conference reported 
ARR 0.66 (95% CI 0.24-1.85)(48) 
 
2.3.4 Bacterial Vaginosis infections 
A prospective cohort study reports a decreased risk of BV in both women who use 
oral contraception and those who use injectable contraception, AORs of 0.76 (95% 
CI 0.63-0.9) and 0.64 (95% CI 0.53-0.76) respectively (15). In a similar study, 
amongst CSW, AHR of 0.8 (95% CI 0.7-1.0) and 0.7 (95% CI 0.5-0.8) for oral 
contraception users and injectable contraception users were reported (25).the 
results from a study presented at an international conference are similar in trend 
ARR 0.85 (95% CI 0.73-0.99) (48).  
Table 1.1 Summary of published literature 
Author Objectives Population Study 
design 
Summarized results Comments 
Cottingham 
and Hunter 
1992 (22)  
To assess the 
strength and 
consistency of the 
association 
between the use 
of OC and CT. 
Many 
different: 
mostly 
studies 
conducted 
in Europe 
and North 
America. 
Quantitative 
review  
• Pooled estimated 
unadjusted OR for 29 
case control studies was 
1.9 (1.77-2.11) neither 
study quality nor 
prevalence affected this 
result. 
• When compared to 
barrier methods the OR 
increased to 2.91 (1.86-
4.55) 
• Review methodology clearly 
described 
• Studies were grouped 
according to whether they 
were prospective or case 
control, data were extracted 
and pooled estimates of 
unadjusted OR were made 
for all 
• Many of the studies were 
cross sectional and case 
control in design 
• Most of the studies were 
secondary analysis of data for 
other objectives 
• Many of the studies did not 
control for confounders 
• Compared single exposure 
(OC) to single outcome 
(Chlamydia) 
Mohllajee 
et al 2006 
(26) 
Review of 
literature 
published  
Many 
different 
populations 
Systematic 
review 
• Wide range of OR 
reported in the 
different studies, no 
summary odd ratios 
calculated 
• Most recent articles included 
in this table under original 
articles  
 
Baeton et 
al 
2001 (25) 
To examine the 
relationship 
between use of 
OC or DMPA and 
CSW, 
Mombasa 
Kenya, HIV 
negative 
Prospective 
cohort  
study 
1202 
• Women using OC were at 
increase risk of CT 
infection HR 1.8 (1.1-2.9) 
and decreased risk of BV  
• Good study design, methods 
well described  
• Length of hormone exposure 
documented 
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STI acquisition. enrolled 
and 948 
included in 
analysis. 
Median 
follow up 
was 421 
days. 
HR  0.7 (0.5-0.8),  
• Non significant  increased 
risk of NG1.4 (0.9-2.1) 
and TV 0.9 (0.7-1.3) 
• Women using DMPA 
were at significantly 
increased risk of CT 
infection HR 1.6 (1.1-2.4) 
and decrease risk of BV 
HR 0.7 (0.5-0.8, TV HR 
0.6 (0.4-1.0) and non 
significant AHR 1.1(0.8-
1.6) for NG infections 
• Consistent condom use 
was associated with a 
significant decrease risk 
of GC, CT and BV.  
• Exposure defined as either 
OC or DMPA 
• Outcomes measure by 
standard laboratory methods 
• Confounders included in 
analysis include age, 
education level, years in 
CSW, parity, number of 
sexual partners, number of 
sexual contacts and condom 
useage.  
Morrison et 
al 2004 (24) 
To measure the 
effect of oral 
contraceptives 
(OC) and DMPA 
on the acquisition 
of cervical 
infections  
Women 
attending 
reproductive 
health 
centres in 
Baltimore, 
USA 
Prospective 
cohort 1003 
women 
enrolled, 
819 
included in 
the 
analysis. 
Follow up 
analysis as 
per 
segment 
exposed to 
hormone.  
• OC not associated with 
infection AHR 1.5 (0.6-
3.5) 
• DMPA was associated 
with infection HR 3.6 
(1.6-8.5).  
• Cervical ectopy was not a 
predictor of infection 
 
• Grouped cervical infections 
together as single outcome. 
• Hormonal exposure well 
documented and commenced 
at start of study 
• Laboratory methods to define 
end points 
• Confounders included in 
analysis age, ethnicity, 
socioeconomic, number of 
partners and condom use. 
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Avontis et 
al 1990  22) 
To estimate the 
incidence of 
genital infection in 
women using 
hormonal 
contraception or 
IUD 
General 
population 
women, in 
Belgium 
Prospective 
cohort , 128 
women on 
OC and 
108 with 
IUD. 24 
months of 
follow up. 
• Crude RR 8.8 (1.3-59)  • OC compared to IUD 
• No confounders in model 
• Single outcome, CT 
 
Lavery et al 
(45) 
To evaluate the 
relationship 
between the use 
of hormonal 
contraception and 
the acquisition of 
cervical STI 
among HIV 
infected women 
HIV positive 
CSW in 
Kenya  
Prospective 
cohort, 242 
women 
contributing 
799 person 
years of 
follow up 
• OC AHR CT 2.2 (0.7-
7.3), NG 0.6 (0.3-1.3) 
• DMPA, AHR CT 3.1(1.0-
9.4). NG 1.0 (0.6-1.7) 
 
• Design similar to other Kenya 
study (23). Women who 
seroconverted in cohort follow 
up for this study. 
• Single exposure, well defined 
• Separate pathogenic 
outcomes defined 
• Good reporting on collection 
of data on confounders 
• Adjusted for confounders in 
analysis 
Rahm et al, 
1991 
(34) 
To describe the 
incidence of CT 
infections in 
sexually active 
teenage girls 
Teenage 
girls in 
Sweden 
Prospective 
cohort. 301 
girls in 1 
year follow 
up 
• RR 0.67 (0.27-1.68) 
• OC only 
• Statistical methods not well 
described, seems to be a 
crude RR.  
• Does describe ectopy and 
changes in this over time 
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Pettifor et 
al 2007(48) 
To describe the 
association 
between the use 
of injectable 
contraception and 
the risk of GC, CT, 
BV and TV 
infections 
Family 
planning 
clinic, South 
Africa 
Prospective 
cohort 
study. 551 
women 1 
year of 
follow up 
• Rate Ratio (RR) 
• ARR CT 1.04(0.62-1.76) 
• ARR GC 1.02 ( 0.50-
2.11) 
• ARR TV 0.66(0.24-1.85) 
• ARR BV 0.85(0.73-0.99) 
• Not yet published in a peer 
review journal 
• Injectable contraception only 
• Small sample size 
• Exposure not defined 
Morrison et 
al 
(2007)(47) 
To describe the 
association 
between the use 
of OC and DMPA 
and the acquisition 
of CT and GC 
Women 
attending 
family 
planning 
clinics in 
Uganda, 
Zimbabwe 
and 
Thailand 
Prospective 
cohort 
study. 6109 
women, 2 
year follow 
up 
• OC AHR CT 1.39(1.09-
1.77) GC 1.7 (1.25– 1.31) 
• DMPA AHR CT 1.09(0.84 
-1.41) GC 1.50(1.10-
2.05) 
• Not yet published in peer 
review journal 
• Large cohort of general 
population women, long 
follow. 
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2.4 Proposed biological changes that may increase the risk of infection  
There are several documented changes that occur in the genital tract associated 
with the use of hormonal contraception that change the normal defense mechanisms 
of the vaginal and cervix leading to an increase in susceptibility to infection. Firstly 
the use of DMPA leads to a hypo estrogenic state which is characterized by thinning 
of the vaginal epithelium which has been demonstrated to increase transmission of 
simian immunodeficiency virus (SIV) in macaques (27). Secondly the use of DMPA 
has been associated with a reduction in lactobacilli resulting in an increase in vaginal 
pH (28-30). A low vaginal pH is thought to contribute to vaginal natural defense 
mechanisms against bacterial and viral infective agents. Thirdly in a state similar to 
pregnancy, the oestrogen and progesterone hormonal influence of contraception 
may suppress the local immune system in the vagina. The importance of these local 
immune changes remains unclear (32, 33.) A forth possible mechanism of action is 
cervical ectopy, which is the extension of the columnar endocervical lining onto the 
outer surface of the cervix. This exposes a single layer of cells and blood vessels to 
trauma during intercourse and infection. Cervical ectopy is common in adolescents 
(33-36), pregnant women (35) and in women who are using oral contraception. (34, 
36, 37) Cervical ectopy has been associated with increased risk of incident CT 
infections, HR 2.3 (95% CI 0.9-6.0) (34, 23) and with prevalent CT infections 
(34,37,38,39). This is caused by the infective agent’s preference for infecting 
columnar epithelium such as is found in the cells exposed by cervical ectopy. 
Interestingly the same associations are not shown for gonorrhea infection (23, 30). 
In addition to the changes in vaginal environment caused by hormonal changes 
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animal studies suggest that progesterone and oestrogen may enhance the growth 
and persistence of the bacteria associated with genital infection. (25, 31, 32). There 
is no evidence that looks specifically at the use of NET-EN or that compares the 
changes in NET-EN uses to DMPA uses. 
    
2.5 Summary 
As the use of hormonal contraception is widespread and forms the backbone of 
family planning services in South Africa and STIs are highly prevalent in South 
Africa, it remains important to consolidate the evidence of the risk of STI in the 
presence of hormonal contraception. Additional concerns about the potential 
increased burden of STI globally, at present, may introduce the need to reassess 
messaging to women using hormonal contraception. The existing data suggests that 
there is an increased risk associated with the use of hormonal contraception and the 
acquisition of STI, particularly CT infections. Although there is not as much data for 
the risk of NG and TV the trends are similar in the available data. The protective 
effect of hormonal contraception use on the acquisition of BV is encouraging, given 
the increased risk of HIV acquisition associated with BV and the impact of BV on 
pregnancy outcomes. Most data have been collected in Europe and America, with 
the exception of the Kenyan cohorts. There is currently no published data that 
describes this association in the South African setting.  
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2.6 Justification for this secondary analysis 
Sexually transmitted infections are still prevalent in South Africa and hormonal 
contraception use is very common (9, 10, 19). The link between the use of hormonal 
contraception and the increased risk of acquisition of STI follows a trend of slightly 
increased risk but no evidence, at this stage, is strong enough to assign causality.  
This secondary analysis of the risk of acquiring STIs in women who use hormonal 
contraception arises from the availability of appropriate data following the conduct of 
a prospective cohort study. This cohort of South African women in an urban setting, 
a setting at high risk of STI, will provide locally appropriate data and will add to the 
evidence collected globally to justify a randomized control trial to document the 
association between the use of hormonal contraception and the acquisition of 
sexually transmitted infections.  
  
2.7 Background to the parent study 
During preparation for a phase three trial of a candidate vaginal microbicide a cohort 
of HIV negative women aged 18 to 35 were enrolled into a prospective cohort study. 
The objectives of the study were to estimate HIV incidence, condom usage and 
cohort retention. Additional inclusion criteria included: in good health, expect to be 
sexually active during the 12-month study period, use the Soweto primary health 
care services regularly, have an identifiable address (or mechanism to make 
contact) during the study, use a recognised method of contraception,  were willing 
and competent to give informed consent, were willing to undergo clinical evaluations, 
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including pelvic examination and specimen collection according to the protocol, and  
were willing to receive regular HIV/STI risk reduction counselling. Enrolled 
participants were screened for CT and NG endo-cervical swab and BV and TV by 
vaginal swab. Participants attended the study clinic 12 weekly for a period of one 
year and were tested for STIs at week 24 and 52. 
   
2.8 Research Question 
Is the use of hormonal contraception associated with incident STI infections in a 
cohort of HIV negative women in Soweto South Africa?   
 
2.9 Objective 
To describe the association between the use of hormonal contraception and incident 
sexually transmitted infections. 
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3.0 METHODS 
This secondary data analysis examines the relationship between the use of 
hormonal contraception and the acquisition of sexually transmitted infections in a 
prospective cohort study conducted in Soweto, South Africa. The cohort of 
volunteers was made up of HIV negative women aged 18 to 35 attending primary 
health care clinics in the Soweto area. Enrolment into the study included written 
informed consent. All 752 women enrolled into the cohort study were included in this 
analysis.  
 
3.1 Clinical procedures 
Women were examined in the clinic at enrolment and then at six and twelve months 
of follow up. All STIs were treated syndromically at the clinic visit and followed up 
with treatment for laboratory diagnosed infections. Genital examination included the 
collection of samples from the vaginal wall for BV and TV. Endocervical specimens 
were collected for CT and NG by a Dacron tipped swab.  Data on exposure variables 
were collected by structured interview conducted by a trained nurse. Data were 
collected, by structured interview, for possible confounder variables; age, level of 
education, type of sexual partner, number of sexual partners and condom use. All 
interview forms were reviewed for quality control in the clinic and again at the data 
centre. Data were double entered into an Epi-Info™ database.  
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3.2 Lost to follow up 
Women were discontinued from the study on the diagnosis of HIV or pregnancy. In 
addition women who did not complete follow up were censored at the last follow up 
visit they attended. Women contributed to the study follow up time up to the last 
clinical visit that they were seen at. 
 
3.3 Measurement of outcome variables 
 The following laboratory based tests were performed to define a sexually 
transmitted infection: Samples for NG and CT were tested qualitatively by 
polymerase chain reaction (PCR) (Amplicor ® Roche Diagnostics Systems, Inc. 
Branchburg, N.J). Swabs taken from the vaginal wall were examined by microscopy 
for the presence of BV and scored by Nugents criteria; a positive BV result was a 
Nugents score of greater than seven. Specimens for TV were cultured in Diamonds 
media and examined qualitatively in the laboratory. For the purpose of this analysis 
each baseline STI was considered treated and cured, so that infections identified at 
the six month or twelve month follow up visits were classified as incident infections. 
For the time series analysis each incident infection provided a failure event, this 
‘failed’ women at the point of diagnosis of infection. This analysis then excludes a 
repeated measure or clustering of a second infection in an individual.  
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3.4 Measurement of exposure variable 
The primary exposure variable considered in this analysis is the use of hormonal 
contraception: specifically the injectable contraception (either DMPA or NET- EN) 
and the oral contraceptive pill. A combined hormonal contraception exposure 
variable was used as the numbers in the separate groups were small. Any form of 
hormonal Participants were asked about their present method use at each of the 
clinical visits; however no retrospective history on length of exposure to hormones 
was recorded nor was any biological confirmation made of hormonal exposure. The 
exposure to hormonal contraception was consider as a baseline exposure and 
switching of methods was not accounted for. The categories of response are defined 
as: injectable contraception either DMPA or NET- EN, oral contraception, condoms, 
sterilized, traditional, intrauterine device or natural methods.  Contraception use was 
regrouped to hormonal and non hormonal. Hormonal methods included the 
injectable contraception (DPMA and NET-EN) and oral contraception and non 
hormonal methods included condoms, sterilized, traditional, IUD and natural 
methods.   
 
3.5 Measurement of possible confounding variables or effect modifying 
variables 
Identification of possible confounders variables was based on evidence from 
previous studies (23,24). These include demographic factors such as age and 
variables that define increased risk of STI infection including marital status, number 
of sexual partner and condom use. 
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Recoding of variables included type of sexual partner which was regrouped to 
include cohabiting partner, not cohabiting and casual partners.  This defines sexual 
risk behaviour where women who do not cohabit with their partners are more at risk 
of STI including HIV. Age was regrouped into age groups to define at risk age 
groups, namely those under 24 (divided into two groups). Education level was 
defined as primary, secondary and tertiary levels of education.  
Vaginal cleansing practices or douching was considered an effect modifier and data 
on these practices were collected by structured interview. Women were asked if they 
had ever practiced douching or not. Douching interferes with the normal vaginal flora 
leading to a decrease in the normal vaginal defenses, adding to the risk of acquiring 
an infection (13). 
 
3.6 Data analysis 
3.6.1 Data cleaning and preparation of the dataset 
Data were double data entered into an Epi-Info™ database. The data set was 
cleaned and the code book was verified by comparing the structured interview 
guides with the dataset. Some recoding had been done on the data base and was 
removed prior to this analysis. The dataset consisted of two separate datasets, one 
for screening, which included the baseline demographic information of all 
participants and a second dataset which contained follow up information. The 
datasets were merged in STATA® version 8 by participant identification number. 
The merge also included a process of excluding variables that were not relevant to 
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this analysis. The final dataset then contained baseline and follow up data on 752 
women.  Variables were then renamed to more simple names to allow for easier 
analysis. Some STI tests were repeated at non clinical visit as laboratory results 
were not available or specimens were inadequate or the visit coincided with menses. 
A process of assigning the laboratory results to a primary clinical visit, either 
baseline, six months or one year was done. This was achieved by tabulating the STI 
results and then listing the unique identifications for STI results assigned to a non 
clinical visit and matching these with missing results for the preceding clinical visit. 
Any additional missing data on either outcome or exposure variable are quantified in 
the result section. 
 
3.6.2 Descriptive statistics 
Descriptive statistics were used to describe the important frequencies and 
proportions of risk factors (type of hormonal contraception use, age, number of 
sexual partners, type of sexual partners, sexual hygiene practices and 
socioeconomic factors) in the cohort for women using hormonal contraception and 
those not using contraception. Comparison by chi square test was done on 
categorical data and by Student t test for continuous data. All frequencies and 
proportions are reported with 95% confidence intervals and p values where 
appropriate. Baseline prevalence of STIs of was calculated and reported as 
proportions.   
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3.6.3 Power calculation 
The cohort sample size is 752 women followed up for one year. Based on this 
sample size a power calculation has been done. The calculation calculated the 
power to detect a difference between using injectable contraception and non 
injectable contraception on the incidence of sexually transmitted infection.  This was 
based on the published work which detected a 3.6 times increased risk of acquiring 
a CT infection (22).  The power to detect a threefold (18% incidence) increase in 
incidence was 99%, the power to detect a smaller difference in incidence decreased 
to 30%.  
Table 3. 1 Power size calculation  
Sample size 
In each group 
 
Incidence              % difference detected           Power 
                            Alpha at 0.05 (2 sided) 
 
376 6% 67% 30% 
376 12% 50% 79% 
376 18% 33% 99% 
 
3.6.4 Survival time analysis 
For the survival time analysis in the ‘long’ format of the data the data was declared 
survival time data (stset).  Each incident infection provided a failure event and time 
to event was calculated on the date of the visit at which the women ‘failed’.  The 
survival time to each infection was plotted on Kaplan Meier curves and a log rank 
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test was used to compare the hormonal and non hormonal contraception users for 
each of the infections. The incidence rate for each infection was calculated and 
reported as an incidence rate per person time to follow up.  
 
3.6.5 Adjusting for confounders and effect modifiers  
A univariate analysis calculated a hazard rate for STIs in the presence of hormonal 
contraception or not for each of the STI. These were calculated in a survival time 
Cox regression model. Cox regression models for unadjusted hazard ratios are 
reported with confidence intervals (95%) and p value.  Univariate analysis for each 
potential confounder was done and hazard ratios with p values of less than 0.10 for 
the separate confounders were then included into the multivariate analysis. 
Confounders were selected as those variables that would potential affect the 
relationship between exposure to hormonal contraception and the acquisition of a 
STI. For example age, marital status, number of sexual partner, condom use and 
education as these variables may affect both the choice of contraception and the risk 
of acquiring an STI. Each confounder was separately entered into a Cox model with 
the exposure to estimate a hazard ratio. If the p value for this model was less than 
0.1 the confounder was included in a final Cox model.  A Cox regression model was 
used as the model allows for the longitudinal time varying nature of a cohort design 
but with a single failure per participant.  
Only douching was considered an effect modifier and so this interaction was 
assessed in a Cox regression model, initially as a univariate comparison and then if 
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the association fitted the criteria of p <0.1, the variable was added to a multivariate 
model with the appropriate confounding variables. 
 
3.6.6 Statistical tests for assumptions and fit of models 
The significance of each model was assessed by the log likelihood and p value. The 
assumption of proportional hazard, which is the only the assumption for a Cox 
regression model, was tested and the graphs to compare the proportional hazards 
over time are reported.  This was tested for by plotting variables over time by the 
“stcoxkm” command and comparing the resulting lines. 
 
3.6.7 Ethics clearance 
This analysis received clearance from the University of the Witwatersrand Human 
Research Ethics committee on 29/08/2008 reference M080842.  The parent study 
received approval from the HREC M02-01-09.  All volunteers were offered 
information sheets in their language of choice (English, IsiZulu or SeSotho) and all 
enrolled volunteers signed informed consent prior to any study procedures taking 
place. Consent was revisited at each clinic contact and the option to withdraw was 
available at any time.  Participants were offered all test results and treatment for 
STIs was available free of charge. Any medical condition that the study staff were 
not able to manage was handled with an assisted referral to a tertiary hospital close 
to the study site. A similar approach was used to social problems with the study site 
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having an extended interactive network of Government and Non Governmental 
Organizations (NGO) referral organizations.  
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4.0 RESULTS 
4.1 Participants 
Figure one illustrates the flow of participants through the study describing the 
reasons for participant withdrawal and loss to follow up. In the period between 
October 2002 and March of 2004 1089 women were screened to enroll 752 women 
into the cohort. Of those screened 264 (24%) were HIV positive 39 (4%) were 
pregnant and the remainder of the screening failures were due to other exclusion 
criteria such as being unwilling to undergo HIV testing, not living in the Soweto area 
and unable to provide reliable contact details. During the study 109 women became 
pregnant and 21 acquired HIV infection, resulting in their discontinuation from the 
study.  Of the 752 women enrolled 544 completed the cohort study (excluding the 
130 that reached the endpoints of pregnancy or HIV infection) leaving an overall 
retention rate for the study of 87%.  All 752 women where included in this analysis. 
In total 567 person years to follow up were recorded.  
 
4.2 Missing data 
At each visit point there are laboratory results missing for participants; this is highest 
for CT and NG. At the first clinical follow up visit 57 (10%) CT results were missing 
and 58 (10%) NG results were missing. At the first clinical follow up visit 35 (9%) of 
BV and 34 (6%) of the TV results were missing. There were fewer missing results at 
the second clinical follow up visit, with the following test results missing;   
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CT 38 (7%), NG 39 (7%), BV 20 (4%) and TV 23 (4%). For this analysis women 
were included until a failure point, this may have been at either the first or second 
follow up visit. So if data was missing at the first visit but there for the second visit 
the second visit would then have formed the failure point. The main reason for 
missing data was inhibition of PCR testing for NG and CT. The reasons for this are 
both the methodology of sampling in the clinic and the limitations of PCR testing. 
The reasons for missing BV and TV results were likely to be participant who 
presented to the clinic during menstruation and other data were collected but the 
biological tests were not done. These missing results may well have affected the 
definition of the outcome variables by misclassification. This missing data was likely 
to be random. 
1089 
screened
752
enrolled
592
Clinical visit 1
544 
Clinical visit 2
87% follow up
567 Person years to 
follow up
Incident infections (n)
CT 37: NG 6: TV21: BV238
Missing results
CT 38: NG 39: TV 23: BV 20
Total HIV and Pregnancy 130 
Incident infections (n)
CT 37: NG 11: TV :15 BV :241
Missing results
CT 57 :NG 58: TV 34: BV 35
Excluded 264(24%) HIV positive: 
39(4%) pregnant 33 (3%) for 
other criteria
 
Clinical assessment and STI 
baseline testing   
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Figure 1 Study flow diagram for women screened for and enrolled into a 
cohort study, Soweto, 2002 to 2004.   
4.3 Descriptive data 
Of the 752 women enrolled, more than half the women (425/56%) used hormonal 
contraception as their preferred method of protection. Of these 110 (26%) used oral 
contraception and 315 (74%) used injectable contraception. The mean age of 
women participating in the study was 24.6 (SD 5) years. As illustrated in table 4.1, 
although the median number of years of education was high (11 years IQR 10-12, 
most women (81%) reported being unemployed. Despite being unemployed, a large 
number of women (66%) had a source of income and the vast majority lived in 
formal housing (91%). There were few differences in baseline characteristic between 
women using hormonal contraception and those not using contraception. Significant 
differences are seen in mean age, age group, women who had ever used a condom 
and type of housing.  Women using hormonal contraception were significantly older 
(p= 0.000 for age group and p=0.003 for mean age) and more likely to live in formal 
housing (p=0.008) and women who did not use hormonal contraception were more 
likely to have used condoms (p=0.000). 
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Table  4.1 Baseline characteristic of women using hormonal contraception and not 
using hormonal contraception in Soweto, 2002 to 2004 (n=752).  
 All women 
N (%) 
Hormonal 
contraception 
N (%) 
Non hormonal 
contraception 
N (%) 
P value 
Age groups  
<20 
20 to 24 
25 to 29 
≥30 
 
101 (13) 
328 (44) 
172 (23) 
151 (20) 
 
41 (10) 
173 (41) 
126 (30) 
85 (20) 
 
60 (18) 
155 (47) 
46 (14) 
66 (20) 
 
0.000 
Level of education  
7 years and less 
8 to 12 years 
> 12 years 
 
81 (11) 
307 (41) 
364 (48) 
 
43 (10) 
186 (44) 
196 (46) 
 
38 (12) 
121 (37) 
168 (52) 
 
0.173 
Socioeconomic markers  
Type of housing 
Informal 
Formal 
 
 
86 (11) 
666 (90) 
 
 
60 (14) 
365 (86) 
 
 
26 (8) 
301 (92) 
 
 
0.008 
 
Ever used a condom  
Yes 
No 
 
594 (79) 
158 (21) 
 
306 (72) 
119 (28) 
 
288 (88) 
39 (12) 
 
0.000 
Number of sexual 
partners (In the last 3 
months) 
no sexual partner 
One 
>1 
 
 
 
2 
638 (92) 
53 (8) 
 
 
 
----- 
372 (94) 
24 (6) 
 
 
 
2 
266 (90) 
21 (10) 
 
 
 
0.048 
Type of partnership 
Married or co-inhabiting 
Regular not co-
inhabiting 
No partner 
 
138 (18) 
591 (79) 
 
23 (3) 
 
138 (20) 
331 (78) 
 
9 (2) 
 
53 (16) 
260 (80) 
 
14 (4) 
 
 
0.017 
Vagina cleansing n(%) 
Yes 
No 
 
51 (7) 
701 (93) 
 
33 (7.76) 
292 (68.71) 
 
18 (6) 
309 (94) 
 
0.222 
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4.4 Sexual risk factors  
At baseline the women in this cohort were at risk for the acquisition of STI. Condom 
use was low. 53% of women did not use a condom at the last sex act and 21% had 
never used a condom. The majority (79%) of women did not cohabit with their 
regular sexual partner.  However the majority of women (92%) reported only having 
one sexual partner and vaginal cleansing practices were not prevalent, only 7% of 
the women reported douching. These risk behaviours are reflected in the measured 
STI prevalences at baseline in the cohort with BV at 53% (95% CI 49 to 57), TV 4% 
(95% CI 1.4 to 5.4), CT 11% (95% CI 8.7 to 13.2) and  NG 2% (95%CI 1 to 3).  
 
4.5 Incident infections 
The incidence rates (Table 4.2)  followed the trend of the baseline prevalences of 
STIs with new BV cases reporting the highest incidence rate of 72 per 100 women 
years of follow up, (95% CI, 63 to 83) for hormonal contraception users. Incidence 
rates for CT infections were 13 per 100 women years of follow up (95% CI, 9 to 17) 
for women using hormonal contraception The number of new TV and NG infections 
were lower, with incidence rates of 6 per 100 women years of follow up (95% CI, 4 to 
10) and 2 per 100 women years to follow up (95% CI, 1 to 4)   respectively for 
women using hormonal contraception.  
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Table 4.2 Incidence rates for STI’s in women enrolled in a cohort study, Soweto 
2002 to 2004. 
 
Hormonal contraception Non hormonal contraception 
 Person 
years 
Incident 
cases 
(n) 
Rate per 
100 person 
years 
(95%CI) 
Person 
years 
Incident 
cases  
(n) 
Rate per 
100 person 
years 
(95%CI) 
CT 311 39 13 (9-17) 241 29 12 (8-19) 
NG 318 6 2 (1-4) 244 10 4 (2-8) 
TV 315 20 6 (4-10) 246 12 5 (3-9) 
BV 266 193 72 (63-83) 206 163 79 (68-92) 
 
 
4.6 Survival time outcomes 
Kaplan Meier graphs for each infection comparing hormonal contraception uses and 
non hormonal contraception uses at visit 1 or visit 2 are illustrated in figure 2.  The 
log rank test for equality shows no significant difference in survival time for any of 
the infections and the group infections (table 4.3). 
32 
 
 
 
Incident CT infections   Incident BV infections 
 
 Incident NG infections   Incident TV infections 
Figure 2 Kaplan Meier Curves for survival to STI infection at either visit 1 or 
visit 2 in a cohort of women in Soweto 2002 to 2004 
 
 
 
 
33 
 
 
Table 4.3 Log rank test for equality of survival times measured for incident STIs in a 
cohort of women in Soweto 2002 to 2004. 
Variable Chi square p value 
CT 0.07 0.79 
TV   0.2 0.66 
NG  2.21 0.14 
BV 0.92 0.34 
 
4.7 Univariate and multivariate  analysis 
4.7.1 C. trachomatis infections 
The univariate analysis for the association between the use of hormonal 
contraception and the acquisition of CT infection describes a HR of 1.07 (95% CI, 
0.66 to 1.72; p= 0.794). The introduction of possible confounders into the Cox 
regression model, as per the entry criterion of p<0.1 in the univariate model, 
suggested confounding by:  
Partner type, where women in not cohabiting partnerships had an increased risk of 
infection, HR 1.79 (95% CI, 0.81 to 3.92; p=0.1) compared to women who were not 
cohabiting with their sexual partners.  
Age group, where women aged 20 to 24 had an increased risk of infection, HR 2.56 
(95% CI, 0.91-7.18; p=0.075) compared to women younger than 20.  
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Level of education, women who had secondary school education or who had  more 
than secondary school education had a lower risk than those who did not complete 
secondary school; HR 0.44 (95% CI 0.22 to 0.87; p=0.018) and HR 0.52 (95% CI 
0.28 to 0.99; p= 0.049) respectively. 
When these potential confounders were entered into the multivariate model, the HR 
for the relationship between the use of hormonal contraception and CT infection 
demonstrated a slightly increased risk of 1.12 (95% CI, 0.69 to 1.82; p0.657) (Table 
4.4). The effect modifier of vaginal cleansing did not fit the criteria for inclusion in to 
a multivariate model for interaction (p= 0.933) for this association.  
 
4.7.2 N. gonorrhoea infections 
The univariate analysis for the association between the use of hormonal 
contraception and the acquisition of NG infection demonstrated a HR of 0.47 (95% 
CI, 0.17 to 1.30; p=0.147). Introduction of possible confounders into univariate model 
did not show any significant confounding nor did any of the possible confounders fit 
the entry criterion for inclusion into a multivariate model (Table 4.4). Likewise vaginal 
cleansing did not meet the inclusion criterion for inclusion in the model (p= 0.874).  
 
4.7.3 T. vaginalis infections 
The unadjusted HR for TV infections was 1.18 (95% CI 0.57 to 2.43; p= 0.059). The 
introduction of confounders suggested confounding by: 
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Number of partners; women who had more than one partner in the last three months 
had a significantly increased risk of TV infections HR 5.19 (95% CI, 1.47 to 18.37; 
p=0.011) compared to women who had only one sexual partner.  
Age group; Women aged 20 to 24 had a decreased risk of infection HR 0.28 (95% 
CI, 0.09 to 0.86; p=0.027) compared to women aged less than 20 years.  
When these confounders were included into a single model the HR for the 
association between hormonal contraception and TV infection decreased slightly 
(adjusted HR 1.06 (95% CI 0.48 to 2.34; p=0.89) (Table 4.4). The effect modifier of 
vaginal cleansing did not fit the entry criterion for inclusion in the model as a test for 
interaction (p0.812). 
 
4.7.4 Bacterial Vaginosis infections 
For the association between hormonal contraception and BV the only possible 
confounder that fitted the criteria for inclusion into a multivariate model was the 
partnership classification of having no regular partner. When this was included into a 
model the univariate HR of 0.90 (95% CI. 0.73 to 1.12; p 0.350) changed very little 
(AHR 0.90 (95% CI, 0.73 to 1.11; p0.34). The univariate consideration of the effect 
of vaginal cleansing suggested that women who practiced vaginal cleansing were 2 
times more likely to acquired BV, HR 2.03 (95% CI, 0.87 to 4.76; p 0.102). This was 
then assessed as an effect modifier in the final model.  The inclusion of these two 
possible confounders or effect modifiers (no regular partner and BV infection) into 
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the multivariate model resulted in the use of hormonal contraception being protective 
for BV infection (AHR 0.27 (95% CI 0.04 to 1.2; p0.081)(Table 4.4). 
 
 
Table 4.4:  Univariate and multivariate analysis results for incident STI infection in a 
cohort of women in Soweto 2002 to 2004.  
 Unadjusted HR Adjusted HR 
Hazard Ratio  
(95% confidence interval) 
P value Hazard Ratio  
(95% confidence interval) 
P value 
CT 1.07 (0.66-1.72)   0.794 1.12 (0.69-1.82)  0.657 
NG 0.47 (0.17-1.30)  0.147 0.47 (0.17-1.30)  0.147 
TV 1.18 (0.57-2.34 0.059 1.06 (0.48-2.34)  0.890 
BV 0.90 (0.73-1.12)   0.350 0.27 (0.05-1.53)  0.140 
 
 
4.8 Comparison of models 
Models were compared by assessing the p value for the model and the log likelihood 
value for the model (Table 4.5).  Although the log likelihood is less for each of the 
multivariate models, the only significant model is the multivariate model for TV 
infections. 
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Table 4.5: Comparison of univariate and multivariate models to assess risk of 
acquiring STIs in a cohort of women in Soweto, 2002 to 2004. 
 Univariate model  Multivarate model 
Log likelihood p value Log likelihood p value 
CT -381 0.794 -374 0.100 
NG -96 0.139 -96 0.139 
TV -172 0.657 -165 0.044 
BV -2047 0.350 -2045 0.172 
 
 
4.9 Test for assumption of Cox regression model 
A test for the only assumption of Cox regression model that the proportion of 
hazards is constant over time was done in STATA® version 8. The graphs illustrated 
that the assumption holds in the main part for each of the outcomes. This is seen in 
the lines of the graphs being parallel (Figure 3). 
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Test for proportional hazard (CT)  Test for proportional hazard (BV) 
 
 
Test for proportional hazard (NG)  Test for proportional hazard (TV) 
 
Figure 3 Test for the assumptions of Cox Regression Model applied to the Cox 
models for the assessment of risk in a cohort of women, Soweto 2002 to 2004.
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5.0 DISCUSSION 
This analysis did not reveal any significant associations between the use of 
hormonal contraception and the acquisition of STIs; however the trends in risk 
mostly mirror the published data (24, 25). Increased risk is suggest with CT infection 
(HR 1.12) but would not be considered clinically significant.  No association is seem 
for TV infection (HR 1.06). Protective effects are seen with GC infection: women 
using hormonal contraception being 53% less likely to acquire GC infection. A much 
larger protective effect is seen for BV infection with women using hormonal 
contraption being 73% less likely to have BV.    
 
Baseline sexually transmitted infection prevalences are similar to those seen in other 
studies (24, 25), although CT (4% vs 11%) and BV (39% vs 53%) infections were 
more prevalent in this cohort. This comparison is interesting as the Kenyan cohort 
consisted of commercial sex workers as opposed to women drawn from the general 
population as in this cohort (25). However, despite this different composition the risk 
profiles for STIs is significantly raised in both cohorts. The high baseline prevalence 
of BV is alarming as BV is considered a risk factor for HIV acquisition (13). BV, a 
change in the normal vaginal flora, is associated with multiple sexual partners and 
vaginal cleansing. Although treatment for BV is effective BV often reoccurs making it 
difficult to sustain a cure (45). The prevalence of NG is lower than other infections 
and may reflect adequate primary health care treatment of NG by syndromic 
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management, although this may have changed in the time since this study was 
completed due to the emergence of NG resistance to Ciprofloxacin. NG infections 
are generally less prevalent in the general population than in high risk groups, such 
as CSW, where frequent partner changes maintain a higher prevalence. Infections 
with CT are more prevalent in this cohort than other infections which may be due in 
part to the asymptomatic nature of the infection which means than women may not 
seek treatment so sustaining a pool of infection in the community. Because CT 
infections are associated with serious complications such as pelvic inflammatory 
disease and infertility the higher prevalence is concerning. Although there are some 
challenges with the development of bedside tests for CT, the use of these tests may 
be considered as an option for pathogen specific testing at a primary health level.  
 
 
 Morrison et al (2004), in his study based in the USA, reported significant 
associations between the use of oral contraception and the acquisition of cervical 
infections. The American cohort had more enrolled  women than this study (1003 vs 
752) which may account for the significant results seen in that study as compared to 
this analysis (24). It is difficult to make a direct comparison between this study and 
the study by Morrison et al, USA, and Baetan et al (2001) in Kenya because the 
Morrison study combined CT and NG infections as a single outcome of cervical 
infection, so increasing the number of incident infections.  Both studies by Morrison 
and Baetan divided the hormonal exposure into OC and DMPA which may assign 
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different risks to the slightly different exposure of combined oral contraception 
(oestrogen and progesterone) and the progesterone only DMPA (24, 25).  
The apparent protective effect of hormonal contraception use on the acquisition of 
gonorrhea (57% decrease in risk) has been reported in other studies including cross 
sectional studies (26). The confidence interval around the hazard ratio is wide in this 
analysis and the true population figure may lie anywhere from 0.41 to 1.32. So it is 
not possible to exclude whether contraception was associated with an increased risk 
of NG infection in this study. Although there is little data on the acquisition of TV 
infections, most studies have reported protective effects of contraception (26). This 
analysis shows a slightly increased risk. A hazards ratio of 1.06 which is not clinically 
significant and wide confidence intervals suggesting that true HR may lie anywhere 
from 0.48 to 2.34 mean that from this analysis we are not able to make an 
association between the use of hormonal contraception and TV infections. The small 
protective effect seen in the acquisition of BV, where women who use hormonal 
contraception are 73% less likely to acquire BV,  AHR 0.27 (0.05 to 1.53) is reflected 
in the Kenyan cohort with both oral contraception (HR 0.8) and DMPA (HR 0.7) 
users demonstrating a decreased risk of acquiring BV infection (25). This protective 
effect is encouraging in a high HIV prevalence setting.  
 
Vaginal cleansing or douching was considered as an effect modifier for this analysis. 
Vaginal cleansing has been associated with changes in the vaginal environment 
such as   the loss of lactobacilli which is also described as an effect caused by the 
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use of DMPA (27-30). When the variable douching was introduced into models for 
the various STI the only association that met the p< 0.1 criteria was for BV where 
women who use hormonal contraception and who practiced douching were two 
times more likely to acquire BV HR 2.03 (0.87 to 4.76; p=0.102).  Although not 
significant this association is expected as vaginal cleansing is considered a risk 
factor for the presence of BV (13).  
 
5.1 Biological plausibility:  
Although there are biological changes documented both macroscopically and 
microscopically in the genital tract in the presence of OC and DMPA (27-30) these 
changes do not reflect in a significant increased risk of infection in this analysis. 
Additional studies suggest a pathogenic effect on causative organisms by hormones 
(25, 31, 32). Again this suggested effect of hormones on pathogens does not result 
in an observed risk in this cohort. In the Morrison cohort study cervical ectopy, which 
has been considered an important mediator for the acquisition of cervical infections, 
was not associated with infection risk (24). The ability to describe the confounding 
influence of cervical ectopy may have added to this analysis. 
  
5.2 Strengths of the study 
5.2.1 Definition of end points 
This study used laboratory based testing for the definition of outcomes; these 
techniques included PCR testing for CT and NG, Nugent scoring for BV and culture 
43 
 
for TV. These techniques all report high sensitive and specificity. Sensitivity and CT 
test on cervical swabs range from 91 to 100% compared with culture sensitivity of 
73% to 93%, and specificity of > 99% for both methods (42).  The alternative to PCR 
for GC is gram stain which is not considered sensitive or specific in women (42).  
Although BV can be diagnosed with a simple bedside test the use of Nugent scoring 
on a gram stain allows quantification of the result. The diagnosis of TV is made by 
microscopy on a wet mount, by culture in Diamonds medium followed by microscopy 
or more recently by PCR.  In a study of 200 women wet mount recorded a 
prevalence of 7%, culture prevalence of 10.5% and PCR 11%. Meaning culture and 
PCR performed similarly (43).   
  
5.2.2 General population, study design and local setting  
This prospective cohort study increases the ability of the study to describe the 
association between exposure and outcomes. The local general population cohort 
could provide information relevant to South African policy makers. 
 
5.2.3 Limitations of the study 
5.2.3.1 Inhibition of PCR and missing lab results 
Inhibition of PCR is a recognised difficulty with this technique. Inhibition of PCR 
testing for CT and NG ranges from 5-9% with 64% of these resolving on repeat 
testing (40). Accurate PCR testing seems to be dependent on sampling methods, 
transport conditions and laboratory preparation (42). During the conduct of this study 
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the high inhibition rates were noted (in excess of 10% of tests). Some tests were 
repeated and retraining of staff was conducted. There are far fewer results missing 
for TV (4-6%) and BV (4-6%), but the loss of incident infections is a possibility. This 
kind of missing data would be considered random as the women who had missing 
results were not necessarily different from those who did not, however bias cannot 
be excluded and statistical methods to deal with missing data may be considered for 
further analysis. For example, multiple imputation methods could be applied (46).  
 
5.2.3.2 Definition of exposure 
The study did not collect data to define the length of time that a woman was exposed 
to hormonal contraception. The study did not exclude or collect information on 
women who may recently have used hormonal contraception and stopped. There 
was no biological confirmation of hormonal levels to measure consistent use of 
hormonal contraception or recent exposure to hormonal contraception. No 
assessment was made in this analysis of women who may have switched 
contraceptive methods or stopped contraceptive methods during the course of the 
study. This may have underestimated the effect of hormonal contraception on the 
risk of acquiring STIs. 
The numbers of women using either oral contraception or injectable contraception 
were small (Injectable 315 (74%) and OC 110(26%)) requiring that these were 
combined into a single analysis. The literature does suggest that the different 
hormonal exposure may result in different risk (24, 25). This measurement may have 
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lead to either over estimation of the exposure (if many women had recently started 
or changed hormonal contraception) or underestimation of exposure if women were 
not consistent on their use of hormonal contraception. 
 
5.2.3.3 No test for cure 
Women were treated at baseline for laboratory and syndromically diagnosed 
infections, however no confirmation of cure was documented. A small number of 
infections may not have been adequately treated resulting in some misclassification 
of outcomes. This may have lead to over estimation of incident infections. 
 
5.2.3.4 Number of incident cases 
In the case of some of the infections, for example NG infections, the number of 
incident infections is low (n=16, single failure infections) which reflects in some of the 
wide confidence intervals and may have underestimated the measure of effect.  
The large number of recurrent BV infections (n=123) may have been better analyzed 
in a repeated measures model to allow for more than one incident infection in a 
woman. The Cox regression model with single endpoint may result in standard 
errors that are too small resulting in narrow confidence intervals and smaller p 
values. 
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5.2.3.5 Measurement of confounders:  
Some potential confounders, for example cervical ectopy, were not measured in this 
study and so were not adjusted for in the analysis. Due to the relatively small sample 
size in this cohort, STIs in women who were pregnant or HIV positive at clinical visits 
were included in the analysis. Pregnancy may have changed the risk of acquiring 
STIs due to the genital tract decrease in immune system function (32, 33). 
5.2.3.6 Cohort structure and loss to follow up 
The cohort was constructed from volunteers who may have been different to women 
who did not volunteer to participate. Similarly women who did not complete follow up 
may have been different to those who did complete follow up. Both these factors 
may lead to bias in the results.  
 
5.3 Conclusion 
There has been wide spread and prolonged interest in association between the use 
of hormonal contraception, either oral or injectable, and the acquisition of sexually 
transmitted infections. The evidence for a significant association is visible in the 
increasing number of cohort studies in different population groups. Because the use 
of hormonal contraception is the foundation of effective family planning worldwide a 
shift in policy would need epidemiological evidence that can assign causality. The 
evidence to support causality would only come from a randomized controlled trial 
with hormonal and non hormonal interventions. To date most scientists have felt that 
randomizing women to contraception would be difficult and unacceptable to patients.  
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However in a study conducted in Jamaica and South Africa women were asked if 
they would consider participating in a trial and would accept randomization: 70% of 
the participants indicated that they would consider randomization to either DMPA or 
an intrauterine device (44).  With this concern aside there may be place for a 
randomized controlled trial to finalise the debate. 
In the interim, public health planning for family planning may consider other 
contraception options like progesterone implants which are a lower dose of 
hormone. The reintroduction of the intra uterine contraceptive device (IUD) may add 
an additional option for women. Health care providers should continue to conduct 
risk assessments with women attending family planning clinics and advise women 
on the need for barrier methods in addition to hormonal contraception to protect 
against STI and HIV acquisition. 
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